Rick E. Winningham - 14 Dec 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: CHIEF EXECUTIVE OFFICER, Director
Issuer ticker: TBPH
Reported as of: 14 Dec 2022
Net transaction value: -$559,500
SEC form: 4
Accepted by SEC: 16 Dec 2022, 18:36:34 UTC
Prior SEC filing: 22 Nov 2022
Next SEC filing: 22 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Brett A. Grimaud, Attorney-in-Fact

Key filing fact

Rick E. Winningham filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 16 Dec 2022.

Key facts

This page summarizes Rick E. Winningham's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 16 Dec 2022, 18:36.

Change

Previous filing in this sequence was filed on 22 Nov 2022.
Current net transaction value: -$559,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Gift

Transaction value
Shares: -9,000
Change %: -0.64%
Price
Shares after: 1,400,797
Date: 13 Dec 2022
Ownership: Direct
Footnotes: F1

TBPH transaction

Ordinary Shares

Sale

Transaction value: $559,500
Shares: -50,000
Change %: -3.6%
Price: $11.19
Shares after: 1,350,797
Date: 14 Dec 2022
Ownership: Direct
Footnotes: F2

TBPH holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 92,567
Date: 14 Dec 2022
Ownership: By Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Bona Fide Gift. No compensation was given to the donor for the gifting of shares.

Footnote F2

This transaction was executed in multiple trades at prices from $11.17 to $11.235 The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected.